Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
about
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cellsA report of lung adenocarcinoma with HIV carrier and the literature reviewNelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activityIdentification of placental transforming growth factor-beta and bikunin metabolites as contaminants of pharmaceutical human chorionic gonadotrophin preparations by proteomic techniques.CD27(-) B-cells produce class switched and somatically hyper-mutated antibodies during chronic HIV-1 infectionRadiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia.Cathepsin L promotes Vascular Intimal Hyperplasia after Arterial InjuryTargeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus.Recent advances in drug repositioning for the discovery of new anticancer drugsKaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversionAnalyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study.Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells.The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitroKaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era.Association between Time on Protease Inhibitors and the Incidence of Squamous Cell Carcinoma of the Anus among U.S. Male Veterans.Antitumour effects of antiretroviral therapy.The role of the tumor microenvironment in HIV-associated lymphomasEmerging therapies for herpes viral infections (types 1 - 8).HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension.Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits Kaposi's sarcoma-associated herpesvirus replication and gene expression.Highbrow proteasome in high-throughput technology.Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapyThe microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategiesDo antiretrovirals reduce the risk of non-AIDS-defining malignancies?Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy.A urinary biomarker profile for children with HIV-associated renal diseases.Pharmacological management of Kaposi's sarcoma.Resistance to TRAIL and how to surmount it.The management of children with Kaposi sarcoma in resource limited settings.KSHV targeted therapy: an update on inhibitors of viral lytic replication.Sequence-specific alterations of epitope production by HIV protease inhibitors.Pulmonary Kaposi's Sarcoma and Its Complications in the HAART Era: A Contemporary Case-Based Review.Identifying the optimal dose of ritonavir in the treatment of malignancies.Diagnosis and Treatment of Kaposi Sarcoma.Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada.Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir.Immunomodulation in female B₆C₃F₁ mice following treatment with the HIV protease inhibitor saquinavir for 28 days by gavage.
P2860
Q24628715-9D4898F0-AC30-4AFC-BDA1-F57BD1FDB46DQ26820860-061CD18B-037D-4AB8-9D37-5F8F91BD69F8Q28083142-0B454D45-0ED9-46D5-B361-8A6008B66950Q31163927-DBFE5D12-0848-4018-BD66-F5F735B826D6Q33438469-634A5E04-7C4D-43E6-8E2F-C70FFADF6E1CQ33638654-37CBCBFB-0F39-4C01-B960-F78232D51C5CQ33714126-AD640A40-5B76-4EBA-B05B-EDA89459E6F4Q33789216-DBAB07AE-A31F-4E55-A03C-9FC8879A6D97Q33793543-DFFFED71-0081-4FFE-BB90-9764889ED303Q33845068-BE7B6A7B-CA2F-4F11-9DEF-E1450D059302Q33888845-511D760C-4926-4FBC-A2FF-22D87E6734E7Q33975107-1B490DB8-22F7-4F09-A2D0-89F662E2BCA7Q34179539-BE2699B5-ABB3-4C1C-BE2C-AE5F30857F8CQ35005190-693ADCDD-D47F-4F56-9ED9-D10531053157Q35557475-B5242ADB-2FCA-4846-A986-7AEB25FB7541Q35858493-05FE92CE-1134-465C-8F2B-9577FAC7C1FBQ35934144-7351996C-23ED-40F2-993E-E820AD838FBBQ35945221-3C799859-F7C3-453E-9A8C-5C137AA35948Q35967376-E9574731-40FC-4AF4-B21F-D555885FE3D9Q36016529-8EC2D1FF-2A0B-44B0-8C31-7015DF9E8D6FQ36364238-5CFE362A-4664-4D3F-A382-76A4BA47B03CQ36381253-4E20F813-580A-4ABE-94C8-04F44033FC43Q36614066-C25E6451-D535-45D9-AEE3-EE8F8C88511BQ37026769-C57F71BB-ECAA-4083-BD31-29D1AC7CA681Q37233212-8DD1058A-A90E-4381-AE76-51E49995B38FQ37415434-21A83B5E-CC97-4413-8CD1-7769BDFDB04EQ37423476-A2E24FE7-9F74-488B-97CA-27025DB96EE8Q37868566-ECCE3FDE-8366-432E-BFE8-3D14B9C5B7F4Q37992546-1154D0DA-16E9-4A9D-AE19-EC748D625DD5Q38068814-707789CD-BAF3-4742-B02C-10C8E4AC4307Q38271135-59D8BE31-0D6F-49C3-8808-4D24F0CAC89BQ38710071-F20C2738-56EC-46C3-8815-CD74A487D597Q38716476-A886C0CD-5814-458B-A638-D7000BDD80EEQ39061564-8E379258-963E-418F-B76C-0750595D4E45Q39190555-6C509896-7F4E-43C3-8D1D-98CB5CE1AC38Q39389293-75D33AB6-8E5D-4B78-BF38-0FDAB9662A3FQ40250347-5DEAFE88-BCB3-4FF6-91B9-A52179D18F63Q40617502-B0A102AB-2E2F-466A-8E83-8B7FF50F5DACQ41026728-DB772A4A-D7E6-42C2-8712-389736E22ECDQ43013087-39F607E1-0AD2-4BE4-976E-17EE02A35DF9
P2860
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
@ast
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
@en
type
label
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
@ast
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
@en
prefLabel
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
@ast
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
@en
P50
P1433
P1476
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
@en
P2093
Giovanni Barillari
P304
P356
10.1016/S1470-2045(03)01192-6
P577
2003-09-01T00:00:00Z